Mahlangu J, Abdul Karim F, Stasyshyn O, Korczowski B, Salazar B, Lucas S, et al. Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study. Res Pract Thromb Haemost. 2022;6(2):e12665.
Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study
By Peter Matlawa|2022-06-07T22:19:42+02:00June 7, 2022|2022 Publication, 2022: January to March|Comments Off on Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study
Share This Story, Choose Your Platform!
About the Author: Peter Matlawa
Related Posts
Correction for Kipkorir et al., “De Novo Cobalamin Biosynthesis, Transport, and Assimilation and Cobalamin-Mediated Regulation of Methionine Biosynthesis in Mycobacterium smegmatis”
Correction for Kipkorir et al., “De Novo Cobalamin Biosynthesis, Transport, and Assimilation and Cobalamin-Mediated Regulation of Methionine Biosynthesis in Mycobacterium smegmatis”
Recency of HIV infection, antiretroviral therapy use and viral loads among symptomatic sexually transmitted infection service attendees in South Africa